QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Acute Blood Purification System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Acute Blood Purification System market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Acute Blood Purification System was estimated to be worth US$ 1680 million in 2025 and is projected to reach US$ 2879 million, growing at a CAGR of 8.0% from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5787674/acute-blood-purification-system 1. Acute Blood Purification System Introduction In 2025, global Acute Blood Purification System production reached approximately 37 k units with an average global market price of around k US$45 per unit. Single-line annual production capacity averages 2,500 units with a gross margin of approximately 27%. The upstream of the Acute Blood Purification System industry primarily encompasses high-performance membrane materials, precision instruments and equipment, as well as control software, which are concentrated in the medical device field. In terms of downstream applications, adult use accounts for more than 80% of the market share, with pediatric applications occupying about 20%. With the increasing number of critically ill patients and the advancement of medical technology, the market continues to grow, and the business opportunities lie in innovative technologies that enhance system performance and expand the global market. The Acute Blood Purification System is a sophisticated device designed to rapidly and effectively remove toxins, excess fluids, and harmful substances from the blood of critically ill patients, typically those in intensive care units. It achieves this through a series of complex processes that ensure the integrity of the patient's blood cells and plasma while isolating and eliminating waste products. The system's ability to provide immediate and targeted treatment is crucial for stabilizing patients with acute conditions such as sepsis, acute renal failure, and drug overdose, where the removal of these substances is vital for survival. The system is engineered to be highly adaptable, capable of handling a wide range of patient-specific requirements, and its compact design allows for seamless integration into existing ICU settings. 2. Acute Blood Purification System Development Factors 2.1. Critical Clinical Needs and Therapeutic Concept Innovation: The Core Engine Driving the Development of Acute Blood Purification Systems The continuous evolution of Acute Blood Purification Systems is fundamentally and most directly driven by the urgent clinical need to treat increasingly complex critical illnesses and the profound transformation in treatment concepts that this demand has triggered. The need for critical care is the fundamental starting point for system development: On one hand, the explosive expansion of the disease spectrum has forced a fundamental upgrade of the systems. The scope of application has long since expanded from the initial management of Acute Kidney Injury to include critical fields such as sepsis (requiring management of the "cytokine storm"), severe poisoning, Acute Respiratory Distress Syndrome, liver failure, post-cardiac arrest syndrome, and immune-mediated diseases. This has led to a fundamental shift in treatment objectives, moving from the past simplistic "renal replacement" and clearance of small molecule toxins to comprehensive "multi-organ function support." Its core tasks have transformed into clearing inflammatory mediators, stabilizing the internal environment, regulating immune imbalance, and buying precious time for the treatment of the underlying primary disease. Simultaneously, the strong clinical pursuit of improving survival rates and prognoses for critically ill patients has directly catalyzed and propelled the innovation of key technologies. For example, to meet the need for more efficient toxin clearance, high-flux dialysis technology has been developed; to ensure the safety of extracorporeal circulation in critically ill patients with coagulation abnormalities (such as those with sepsis or liver failure), precise regional citrate anticoagulation technology has been deeply integrated into modern systems. The simultaneous innovation in treatment concepts forms the ideological cornerstone of technological development: The medical community recognized that for critically ill patients with hemodynamic instability, traditional intermittent, non-physiological treatment modes might pose additional risks. Consequently, the treatment paradigm has comprehensively shifted from "intermittent therapy" to "continuous support." The establishment of the Continuous Renal Replacement Therapy concept not only required devices to provide smooth, continuous treatment but also elevated the role of blood purification from a passive organ function substitute to an "organ support platform" capable of actively and continuously intervening in the disease process (such as continuously clearing inflammatory mediators to interrupt the vicious cycle of sepsis). It is precisely the constantly emerging urgent needs in clinical practice for safer and more effective intervention in more complex diseases, intertwined and mutually reinforced with the conceptual innovations shifting from "replacement" to "support" and from "intermittent" to "continuous," that together constitute the strongest and most direct core driving force behind the technological integration, modal innovation, and material research and development of Acute Blood Purification Systems. 2.2. Integration of Medical Research and Technology Translation: The Dual Engine Propelling the Precision Development of Acute Blood Purification Systems The development of Acute Blood Purification Systems is profoundly influenced by interdisciplinary integration and the fusion of clinical research, with this systematic progress stemming from the close combination of medicine and engineering and the direct guidance of clinical studies. In terms of the medicine-engineering combination, close collaboration between clinical experts and engineering technicians translates actual clinical needs into specific technical parameters and device functionalities. For instance, addressing the challenge of achieving high convective volume in patients with Acute Kidney Injury or multiple organ failure, through optimizing filter design and automated control algorithms, has given rise to advanced automated replacement fluid regulation technology. This ensures the stability of fluid balance and enhances clearance efficiency while reducing the risk of complications such as hypotension or electrolyte disturbances. Furthermore, guided by clinical research, high-level studies such as large-scale Randomized Controlled Trials provide direct evidence-based guidance. For example, research comparing the efficacy differences between Continuous Renal Replacement Therapy and intermittent hemodialysis has driven improvements in system modular design and intelligent monitoring functions. Specialized treatment studies targeting specific diseases like sepsis or acute poisoning have directly driven innovation in dedicated consumables, such as the development of highly efficient adsorption columns for selectively removing inflammatory mediators or toxins, thereby enhancing the system's targeting and overall therapeutic efficacy. This fusion mechanism not only accelerates the translation of devices from laboratory prototypes to clinical applications but also, through a continuous cycle of practical feedback, promotes comprehensive optimization of the system's safety, portability, and cost-effectiveness, ultimately enabling precise intervention and improved prognosis for critically ill patients. 2.3. Policy and Paradigm Shifts: Key Drivers in the Evolution of Acute Blood Purification Systems The development of Acute Blood Purification Systems is deeply driven by the dual forces of treatment concept innovation and the guidance of policies and industry standards. This profound transformation has fundamentally reshaped the clinical positioning, technological pathways, and market access criteria for these systems. At the level of treatment concepts, the paradigm shift from traditional "intermittent" to "continuous" therapy has become a core driving force. The medical community has gradually recognized that for critically ill patients, such as those with Acute Kidney Injury, septic shock, or Multiple Organ Dysfunction Syndrome, slow and continuous solute clearance and fluid management are more conducive to maintaining hemodynamic stability, preventing further organ damage, and protecting the internal environment. Consequently, the concept of Continuous Renal Replacement Therapy was rapidly established and became a core support modality in intensive care. This propelled the evolution of systems from early Continuous Arteriovenous Hemofiltration to modern, high-precision continuous modes like Continuous Veno-Venous Hemofiltration and Continuous Veno-Venous Hemodiafiltration. Simultaneously, the treatment goal shifted from mere "replacement support" to "active therapy." Blood purification is no longer seen as passively replacing renal function but rather as a strategy to directly intervene in the disease process. Through high-volume convection, adsorption, or combined modalities, it actively clears inflammatory mediators, endotoxins, cytokines, and toxic metabolites, thereby significantly improving the prognosis of conditions like sepsis, acute poisoning, and heat stroke. Regarding policy and standard guidance, documents issued by the National Health Commission of China, such as the "Standard Operating Procedures for Blood Purification (2021 Edition)" and "Quality Control Indicators for Nephrology Specialty (2020 Edition)," define requirements for treatment quality, safety, and standardization. This has compelled devices to comply with standards like YY 0645-2018 "Continuous Blood Purification Equipment," necessitating enhancements in anticoagulation management, hospital infection control, and the attainment of monitoring indicator targets. Furthermore, healthcare payment policies have incorporated key functions such as blood temperature, blood pressure, blood volume, and online urea monitoring into the guide for pricing medical service items in the urological system. This directly guides device research and development to integrate intelligent online monitoring modules to qualify for compliant reimbursement. In some regions, Hemodiafiltration has been separately itemized and optimized in payment standards, further incentivizing system upgrades towards precision, modularity, and portability. This synergistic effect of conceptual innovation and policy/standard guidance has not only accelerated the transformation of Acute Blood Purification Systems from supportive tools to active intervention platforms but has also, through raised access thresholds and quality control imperatives, significantly enhanced the systems' safety, efficacy, and clinical accessibility, ultimately aiding critically ill patients in achieving better organ protection and survival benefits. 3. Acute Blood Purification System Development Trends 3.1. Technological and Material Innovation: The Core Engine for Performance Leap in Acute Blood Purification Systems The evolution of Acute Blood Purification Systems is fundamentally and most directly driven by endogenous forces stemming from continuous technological innovation and breakthrough advancements in key materials. This developmental dimension is fundamentally reshaping the therapeutic efficacy, clinical safety boundaries, and breadth of application scenarios for these systems. The most immediate factor propelling this process is the rapid iteration of medical technology itself and the cutting-edge exploration in materials science. For instance, intelligent polymer materials with specific targeting functionalities (such as stimulus-responsive polymers that alter permeability in response to specific pH levels or concentrations of inflammatory mediators) and heparin-mimicking materials with excellent biocompatibility are being applied in the optimized design of next-generation blood purification membranes and adsorbents. These innovations aim to achieve highly selective and efficient clearance of key inflammatory mediators (such as IL-6, TNF-α) in the "cytokine storm" of sepsis or specific protein-bound toxins in acute poisoning, thereby surpassing the limitations of traditional non-selective filtration and adsorption. The direct clinical manifestation of this technological upgrade is the increasingly prominent role of extracorporeal blood purification modalities such as hemoadsorption in treating complex inflammatory states like septic shock and severe pancreatitis. Their high-efficiency, targeted clearance capabilities are driving innovation in treatment strategies. The primary force enabling the transition of these advanced technologies from the laboratory to the clinic stems from the increasingly severe disease burden and clinical demand: the vast global population of chronic kidney disease (CKD) patients, coupled with the increased risk of progression to acute kidney injury (AKI), and the frequent occurrence of various acute poisoning events (such as drug overdose, biological toxins), together constitute an urgent and persistently growing market demand for more efficient and safer purification devices. Against this backdrop, significant growth in global research and development investment, along with the deep cross-integration of materials science, bioengineering, and clinical medicine, constitute the core trends and key supporting factors for accelerated development. This interdisciplinary integration not only fosters the aforementioned innovative materials but also drives the intelligent transformation of the overall system—for example, integrating advanced materials with precise sensors and automated control algorithms to achieve real-time monitoring of filter functional status and automatic optimization of treatment parameters. In summary, it is precisely the core engine of technological and material innovation that directly addresses and leads clinical demand, driving Acute Blood Purification Systems through a profound transformation from "industrial equipment" reliant on traditional dialysis principles to an "intelligent therapeutic platform" based on precision biomedical engineering, thereby providing more powerful tools for critical care. 3.2. Intelligent and Precision-Driven Innovation: The Core Impulse for Acute Blood Purification System Development The development of Acute Blood Purification Systems is undergoing a profound paradigm shift, with its core driving force increasingly focused on the deep integration of intelligent and personalized treatment. This is not only the inevitable direction of technological advancement but also a fundamental requirement for addressing current and future complex clinical challenges. The most direct factors prompting this trend stem from the accelerated global process of population aging and the accompanying high prevalence of chronic diseases: for example, the continuous rise in the prevalence of end-stage renal disease (ESRD), whose patient population often has comorbidities such as cardiovascular and cerebrovascular diseases and diabetes, makes the pathophysiological state during critical illness extremely complex and highly individualized; especially in regions like China, despite the vast patient base of ESRD, treatment rates remain at a relatively insufficient level (some estimates are below 20%). This not only reveals a huge unmet clinical need but also signifies immense potential for improving prognosis in the future by enhancing treatment accessibility and precision. It is precisely this urgent demand for individualized and precise treatment plans that directly drives the necessity for systems to transcend the traditional "standardized prescription" model. The main technological support and core factors for achieving personalized treatment lie in the comprehensive rise of digital medical technologies and the deep application of big data and artificial intelligence (AI). Future advanced Acute Blood Purification Systems will deeply integrate AI algorithms and machine learning models. By monitoring patients' dynamic physiological parameters (such as hemodynamic indicators, electrolyte levels, inflammatory markers, clearance efficiency) in real-time and continuously, and analyzing this data alongside multivariate patient information from electronic medical records and genomics, these systems will achieve real-time dynamic optimization and customization of treatment. For instance, during the implementation of Continuous Renal Replacement Therapy (CRRT), the system could, based on intelligent analysis of the patient's real-time volume status and solute clearance kinetics, automatically and precisely adjust ultrafiltration rates, replacement fluid composition, and anticoagulant dosage. This would achieve optimal purification goals (e.g., efficiently clearing inflammatory mediators of specific molecular weights) while minimizing complications such as hypotension and electrolyte disturbances, realizing a shift from "population-based treatment standards" to "one person, one strategy" precision intervention. This fundamental shift from standardization to intelligent precision is redefining the value of Acute Blood Purification Systems—they are not merely treatment devices executing extracorporeal circulation but are evolving into clinical decision-support and automated treatment platforms that integrate real-time monitoring, intelligent decision-making, and precise execution. This trend will significantly enhance treatment efficiency, safety, and accessibility, ultimately providing superior survival benefits and quality of life for the growing population of critically ill patients with complex conditions. 3.3. Market, Policy, and Clinical Dynamics: Multidimensional Forces Shaping Acute Blood Purification Systems The Acute Blood Purification System, as a critical device in critical care medicine, is currently and will continue to be directly propelled by multifaceted factors including market expansion and the deepening of clinical applications. On the market and industry front, policy liberalization and capital investment constitute the most direct driving forces: In recent years, the relaxation of policies allowing social capital to enter fields such as third-party dialysis centers has greatly stimulated market vitality, providing a strong foundation for the expansion of the renal treatment field, including acute blood purification. The vast patient base of end-stage renal disease (ESRD) (with China accounting for approximately 30% of the global total) and the continuously surging demand for critical care treatment behind it form the primary foundation for the growth in system demand. Against this background, the trend of accelerating localization is becoming increasingly evident. Domestic equipment manufacturers are continuously enhancing their product capabilities through technological catch-up and policy support. This will not only effectively reduce the procurement and application costs of devices, improving accessibility across healthcare institutions at all levels but also benefits from the resumption of procurement in public hospitals and policy guidance for large-scale medical equipment renewal. Together, these factors create unprecedented opportunities for the refinement and popularization of the domestic acute blood purification industry chain. Simultaneously, on the clinical demand side, the continuous expansion of clinical application scenarios and the innovative integration of treatment modalities are pushing the system toward a broader and more profound stage of development. Its application domain is rapidly expanding from the core treatment of traditional acute kidney injury (AKI) to the management of various other critical conditions, including acute poisoning, sepsis, severe parasitic infections (such as malaria), and immune-mediated diseases. The most direct clinical driving factors originate from new and emergent public health events (such as the COVID-19 pandemic) and the frequent occurrence of various acute critical illnesses. These complex cases create an urgent demand for extracorporeal life support technologies, spurring the exploration of new treatment strategies in clinical practice. For instance, clinicians have begun experimenting with sequential or combined application of various blood purification modes, such as therapeutic plasma exchange and continuous renal replacement therapy, to address complex pathological states that cannot be resolved by a single modality. The main support for the development of this multimodal integration trend lies in the continuous accumulation of evidence from relevant high-quality clinical research worldwide and the maturation of multidisciplinary team collaborative diagnosis and treatment models involving critical care medicine, nephrology, infectious diseases, and other specialties. Future clinical development trends will place greater emphasis on the individualization and precision of treatment. By integrating different purification principles, the aim is to efficiently remove pathogenic substances (such as inflammatory mediators, parasitic toxins) while maximizing the safety of the treatment process, thereby overall enhancing the success rate of rescuing complex critically ill patients and having a profound impact on the treatment concepts and practices within the entire field of critical care medicine. In summary, the industrial thrust constituted by market and policy factors, combined with the technological pull formed by the expansion of clinical demand, are jointly shaping the developmental path of Acute Blood Purification Systems, propelling their continuous evolution toward greater accessibility, precision, and efficiency. 4. Leading Manufacturer in the Industry 4.1. Fresenius Medical Care Fresenius Medical Care is a global provider of medical technology and services centered on the treatment of kidney diseases, specializing in delivering a comprehensive range of products and services for patients with chronic and acute kidney failure throughout the entire dialysis care continuum. Its offerings encompass clinical dialysis equipment, hemodialysis machines, dialysis consumables, specialized filters, and treatment protocol support, among other areas. Through its worldwide network of dialysis centers and a complete portfolio of kidney disease treatment products, the company provides healthcare institutions and patients with technical support spanning from basic extracorporeal blood purification products to complex clinical treatment processes, aiming to enhance the treatment experience and quality of life for kidney disease patients. Fresenius Medical Care is committed to continuously driving innovation in the management of chronic kidney disease and related clinical care while optimizing its products and services to meet the clinical needs of different regions and healthcare institutions, which is central to its ongoing business development. In the field of acute blood purification systems, Fresenius Medical Care provides extracorporeal blood purification therapy platforms applicable to intensive care environments, primarily centered on Continuous Renal Replacement Therapy (CRRT) and extended extracorporeal purification treatment modes for clinical support. Its representative product, the multiFiltratePRO, is specifically designed for the management of acute kidney injury and fluid and metabolic balance in critically ill patients. It aids in the removal of uremic toxins and regulation of fluid load through stable continuous purification methods and can be integrated with strategies such as regional citrate anticoagulation to enhance anticoagulation safety. The multiFiltratePRO supports multiple CRRT treatment modalities and can function as a multimodal platform for extracorporeal purification therapy, interfacing with other purification components to remove pathogenic factors from the blood or for purposes such as therapeutic plasma exchange, making it suitable for a broader range of acute purification needs. Additionally, Fresenius Medical Care’s product and service ecosystem in the acute blood purification field includes related filters, consumables, and care support protocols, all aimed at delivering flexible and efficient extracorporeal blood purification solutions for critical care scenarios such as the ICU. 4.1.1. Key Features of multiFiltratePRO The multiFiltratePRO is an advanced therapeutic platform specifically developed for extracorporeal blood purification therapy in critically ill patients within intensive care units (ICUs), designed to support the clinical application of various acute blood purification therapies, particularly serving as a core system for Continuous Renal Replacement Therapy (CRRT). The device integrates long-term clinical experience and advanced technology in its design, enabling the delivery of continuous renal replacement therapy to assist in managing fluid balance and metabolic disorders in patients with acute kidney injury. It incorporates built-in Regional Citrate Anticoagulation (Ci-Ca) options to enhance anticoagulation safety and reduce bleeding risks, while also supporting extended applications such as Therapeutic Plasma Exchange (TPE) and integration with adsorption components from other manufacturers to remove harmful substances from the blood, thereby adapting to a broader range of purification needs. The multiFiltratePRO can also be paired with a low-flow extracorporeal carbon dioxide removal module (multiECCO2R) for CO₂ removal therapy. It is equipped with an intuitive large touchscreen interface, intelligent fluid monitoring, and HL7 connectivity features to enhance operational convenience and clinical information integration, providing healthcare teams with a reliable, flexible, and efficient blood purification therapy platform in complex critical care environments. 4.2. Baxter Baxter is a multinational American medical technology company whose business centers on providing clinical therapeutic products and solutions to global healthcare systems. Its product line encompasses a broad range of medical supplies and therapeutic equipment, including intravenous fluids, drug infusion systems, and nutritional therapy products for critical patient care, as well as products related to kidney disease treatment and extracorporeal blood purification. The company emphasizes supporting healthcare professionals in enhancing efficiency and safety in clinical practice through medical innovation, collaborating with hospitals, intensive care units, and other medical institutions to address complex clinical needs, while continuously developing medical technologies and services suitable for various treatment scenarios. Baxter's overall business revolves around improving the quality of patient care and promoting clinical advancement, with its product portfolio designed to assist clinical teams in achieving better outcomes across multiple care and treatment pathways. In the field of acute blood purification systems, Baxter provides extracorporeal blood purification therapy platforms and integrated solutions suitable for intensive care environments to support renal replacement therapy and blood purification treatments for critically ill patients. Its representative platform, the PRISMAX System, is used to implement Continuous Renal Replacement Therapy (CRRT) and supports modes such as Therapeutic Plasma Exchange (TPE). It allows for the adjustment of purification strategies based on patient conditions to meet diverse clinical needs, while also being compatible with filters and purification components for extended therapies such as inflammatory cytokine removal. The system features an intuitive human-machine interface, intelligent fluid management, and safety control designs, enabling healthcare professionals to effectively carry out treatment processes such as fluid removal and solute clearance. It is complemented by dedicated filters and consumables to enhance treatment flexibility and safety. Additionally, Baxter offers specific blood purification kits that can be used for extracorporeal purification therapies such as CRRT and sepsis management, thereby expanding the scope of acute blood purification applications. 4.2.1. Key Features of PRISMAX System The PRISMAX System is an extracorporeal blood purification therapy platform designed for critically ill patients in intensive care settings. It is primarily used to implement Continuous Renal Replacement Therapy (CRRT) and supports acute blood purification modes such as Therapeutic Plasma Exchange (TPE), offering the flexibility to meet the diverse needs of patients across different body weights and clinical conditions. The system aims to empower healthcare professionals with greater confidence and safety in delivering CRRT, providing personalized and effective treatment regimens for critically ill patients in the intensive care unit. It optimizes the processes of fluid removal and solute clearance while incorporating features such as an intuitive touchscreen interface, intelligent alarm systems, and automated fluid management to simplify treatment setup and enhance operational efficiency. The PRISMAX System supports seamless switching between various CRRT modes based on prescribed protocols and is compatible with different types of purification membranes and filters to achieve diverse clinical objectives. By utilizing integrated accessories such as blood warmers, it controls the temperature of returned blood, thereby improving patient tolerance during extracorporeal blood purification procedures. Its design is informed by feedback from frontline clinical experts, emphasizing treatment accuracy, procedural simplicity, and system stability. This makes it a critical medical device for efficiently and safely implementing continuous extracorporeal blood purification therapies in ICU settings for conditions such as acute kidney injury and fluid overload. 4.3. NorrDia NorrDia is a medical technology company dedicated to providing medical products for patients with chronic and acute kidney diseases, with its business core centered around renal therapy and extracorporeal blood purification. The company's mission is to "help clinical professionals improve the quality of care," achieved through the design, production, and distribution of a series of medical devices and consumables that support renal replacement therapy, blood purification, hemodialysis, and related care processes, while also covering auxiliary clinical products such as nutritional delivery. NorrDia's product portfolio includes continuous renal replacement therapy devices, hemofilters and infusion consumables, hemodialysis-related products, and other acute blood purification consumables. The goal is to provide reliable, simple, and clinically valuable solutions for critically ill and long-term kidney disease patients, while enhancing healthcare professionals' ability to apply these products and treatment methods through training and services. In the field of acute blood purification systems, NorrDia offers extracorporeal blood purification therapy solutions based on the Aquarius™ platform, primarily covering key purification modes such as Continuous Renal Replacement Therapy (CRRT) and Therapeutic Plasma Exchange (TPE), while also supporting other extended extracorporeal blood purification therapies. The Aquarius™ system can implement CRRT in adults and low-volume patients, and is configurable with different software options, such as the classic mode and software equipped with Regional Citrate Anticoagulation (RCA) functionality, to meet clinical needs for personalized anticoagulation approaches. The system achieves precise management of blood and fluids through integrated pumps, an intuitive interface, and safety control devices, and features functions such as total fluid loss management to enhance treatment accuracy. In addition to CRRT, the Aquarius™ system can also be used for TPE and hemoperfusion therapy, and can be combined with consumables such as hemadsorbers to support extracorporeal blood purification therapies related to organ support. NorrDia also provides supporting products for CRRT, including filters, bloodline sets, and anticoagulant solutions, and covers related acute purification consumables to enhance the applicability and flexibility of overall clinical treatment. 4.3.1. Key Features of Aquarius™ Systems NorrDia Aquarius™ Systems Acute Blood Purification System is a high-performance blood purification platform specifically designed for continuous renal replacement therapy (CRRT) in critically ill patients. It can be used for continuous renal replacement therapy in adults and low-body-weight patients (≥20 kg) and can be extended to support other blood purification modes such as therapeutic plasma exchange (TPE) and hemoperfusion. The system core includes precise blood and fluid pumps, an intuitive and easy-to-use human-machine interface, integrated safety protection mechanisms, and electronic scales. It features the innovative Total Fluid Loss Management (TFL) function, which automatically compensates for potential fluid discrepancies during treatment, ensuring close alignment between the actual infusion and the prescribed dose. This supports clinical precision in fluid and efficacy management. The Aquarius™ can be configured with different software versions, such as the standard Platinum software or the Aquarius+ software with Regional Citrate Anticoagulation (RCA). This allows medical staff to easily switch between heparin and citrate anticoagulation modes based on the patient's metabolic status, enabling flexible adjustment of the treatment plan without the need to replace the bloodline components. For low-body-weight patients, a dedicated RCA kit is also available to facilitate personalized anticoagulation strategies. The device is compatible with a variety of disposable bloodline sets and filters. Its modular design enhances operational convenience and maintenance efficiency. It serves as an essential clinical tool in ICU and critical care settings for implementing multimodal acute blood purification therapy, optimizing renal replacement, and providing multi-organ support. 4.4. Bbraun B. Braun is a globally leading medical technology company committed to providing comprehensive medical products and solutions for clinical care. Its business spans multiple areas including smart infusion therapy, safe and efficient pharmacy products, surgical instruments and nursing consumables, blood purification and kidney therapy. It offers systematic support to healthcare institutions, medical professionals, and patients, ranging from basic clinical care to complex treatments. Through innovation-driven efforts, the company continuously optimizes its product portfolio and services, with a primary focus on patient safety and clinical efficacy, thereby promoting the continuous improvement of healthcare systems. Simultaneously, it engages in cooperation, education, and training across multiple countries and regions worldwide to enhance healthcare service capabilities and improve the quality of patient care. In the field of acute blood purification systems, B. Braun provides extracorporeal blood purification platforms and integrated solutions suitable for critical care, covering key purification modalities such as Continuous Renal Replacement Therapy (CRRT) and Therapeutic Plasma Exchange (TPE). Its core product, the OMNI® Acute Blood Purification System, supports multiple CRRT modes including Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), Continuous Veno-Venous Hemodiafiltration (CVVHDF), and Slow Continuous Ultrafiltration (SCUF). It can also perform TPE, enabling flexible switching between different treatment methods based on the patient's condition to meet clinical needs such as acute kidney injury, fluid overload, and metabolic disorders. The OMNI® also serves as a multi-organ support platform, capable of being used in conjunction with secondary adsorbers or filtration components for additional extracorporeal purification therapies. It features designs such as intelligent fluid management, an intuitive operation interface, and pre-installed bloodlines to enhance the flexibility and safety of daily purification treatments in the ICU. 4.4.1. Key Features of OMNI® The B. Braun OMNI® Acute Blood Purification System is an advanced extracorporeal blood and plasma purification therapy device specifically designed for intensive care settings. It is a comprehensive, integrated platform capable of delivering a variety of blood purification therapies and anticoagulation management, supporting critical needs in critically ill patients such as renal replacement, fluid balance regulation, toxin removal, and other complex treatment requirements. It serves as a core device for acute blood purification therapy in the ICU. The system integrates a complete suite of Continuous Renal Replacement Therapy (CRRT) modes, including Continuous Veno-Venous Hemofiltration (CVVH), Continuous Veno-Venous Hemodialysis (CVVHD), Continuous Veno-Venous Hemodiafiltration (CVVHDF), Slow Continuous Ultrafiltration (SCUF), and Therapeutic Plasma Exchange (TPE). Furthermore, it can function as a multi-organ support platform, connecting with secondary adsorbers or filtration components for extended therapies such as CO₂ removal or cytokine adsorption. The OMNI® features an intelligent fluid management system that automatically adjusts blood flow and fluid volumes to reduce alarm frequency and compensates for therapy dose during brief interventions, ensuring a prescription dose delivery rate of approximately 98% and a downtime of only about 5%. This contributes to optimized clinical purification efficiency and therapeutic efficacy. The device design emphasizes clinical operational ease, utilizing pre-connected OMNIset® Plug & Play disposable bloodline sets that significantly reduce setup and priming time (approximately 10-11 minutes). It is equipped with an intuitive human-machine interface, a barcode recognition system, a mobile and lightweight body, adjustable display/quiet mode settings, and supports emergency battery power for short-term operation during power outages, thereby enhancing efficiency and safety within the ICU workflow. The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively. The Acute Blood Purification System market is segmented as below: By Company Fresenius Medical Care Baxter NorrDia Bbraun JMS SB-KAWASUMI Infomed Asahi Kasei Medtronic Chongqing SWS Hemodialysis Care Zhuhai Jafron Biomedical Beijing Weili Medical Guangdong Biolight Meditech Segment by Type CRRT Therapies TPE Therapies Other Therapies Segment by Application Adult Patient Pediatric Patient Each chapter of the report provides detailed information for readers to further understand the Acute Blood Purification System market: Chapter 1: Introduces the report scope of the Acute Blood Purification System report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032) Chapter 2: Detailed analysis of Acute Blood Purification System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026) Chapter 3: Provides the analysis of various Acute Blood Purification System market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032) Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032) Chapter 5: Sales, revenue of Acute Blood Purification System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032) Chapter 6: Sales, revenue of Acute Blood Purification System in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032) Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026) Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion. Benefits of purchasing QYResearch report: Competitive Analysis: QYResearch provides in-depth Acute Blood Purification System competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge. Industry Analysis: QYResearch provides Acute Blood Purification System comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis. and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions. Market Size: QYResearch provides Acute Blood Purification System market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development. Other relevant reports of QYResearch: Global Acute Blood Purification System Market Outlook, In‑Depth Analysis & Forecast to 2032 Global Acute Blood Purification System Market Research Report 2026 Global Acute Blood Purification System Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032 About Us： QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com Email: global@qyresearch.com Tel: 001-626-842-1666(US)   JP: https://www.qyresearch.co.jp